[ad_1]
The American company Moderna announced on Monday that it has begun the initial phase of a clinical trial for a new candidate vaccine against Covid-19, which could be stored and transported in refrigerators instead of freezers, Reuters reports, taken over by news.ro. The new candidate vaccine could be easier to distribute, especially in developing countries, where distribution problems could create problems for vaccination campaigns.
[ad_2]
The early-stage study will evaluate the safety and immunogenicity of the next-generation vaccine, called mRNA-1283, which is designed to be given in three doses. The vaccine will be administered to healthy adults, both in a single dose and in two doses, every 28 days.
Moderna also intends to evaluate the new vaccine, mRNA-1283, as a possible booster in future studies.
Moderna began next week injecting the first participants in a study to test candidate vaccines for Covid-19 that target the B.1.351 variant, which first appeared in South Africa.
The candidate booster vaccine called mRNA-1273,351 will be tested in a clinical trial as a specific vaccine and a multivalent vaccine, according to a company announcement.
